LINC02919: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

Target Name: LINC02919

NCBI ID: G105378032

LINC02919

Other Name(s): long intergenic non-protein coding RNA 2919 | Long intergenic non-protein coding RNA 2919

LINC02919: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

Introduction

LINC02919 is a long intergenic non-protein-coding RNA (lncRNA) that has been identified using RNA-seq technology. This RNA is different from traditional proteins in that it is not made by translation of mRNA, but rather by the process of RNA biosynthesis . LINC02919 has been shown to play a role in various cellular processes, including cell adhesion, migration, and invasion. Its function as a drug target and biomarker has also been suggested, making it an attractive target for research and development of new therapeutics.

Drug Target Potential

LINC02919 has been shown to be involved in several cellular processes that are relevant to drug development. Its function in cell adhesion and migration has been implicated in the development of cancer. For example, LINC02919 has been shown to be involved in the regulation of tight junctions , which are a type of cell-cell barrier that helps to maintain tissue structure and prevent the movement of harmful substances into the body.

Additionally, LINC02919 has also been shown to be involved in the regulation of cell proliferation. It has been shown to inhibit the activity of the oncogene transforming growth factor-?? (NF-kappa), which is a key regulator of cell proliferation. This suggests that LINC02919 may have potential as an anti-cancer drug by inhibiting the growth of cancer cells.

Biomarker Potential

LINC02919 has also been shown to be involved in the regulation of cell death, which is an important aspect of cancer progression. It has been shown to play a role in the regulation of apoptosis, which is a natural form of cell death that helps to remove damaged or dysfunctional cells from the body.

Additionally, LINC02919 has also been shown to be involved in the regulation of cellular signaling pathways. It has been shown to play a role in the regulation of theNotch signaling pathway, which is involved in the regulation of stem cells and their differentiation. This suggests that LINC02919 may have potential as a biomarker for the diagnosis and prognosis of various diseases.

Expression and Regulation

LINC02919 has been shown to be expressed in a variety of tissues and cells, including brain, pancreas, and heart. It has also been shown to be involved in the regulation of cellular processes, including cell adhesion, migration, and invasion.

To better understand the regulation of LINC02919, researchers have used techniques such as RNA sequencing and RNA-profiling to study its expression and regulation. RNA sequencing has shown that LINC02919 is expressed in a variety of tissues and cells and is regulated by a variety of factors , including transcription factors, miRNA, etc.

Conclusion

In conclusion, LINC02919 is a long intergenic non-protein-coding RNA that has been shown to play a role in various cellular processes. Its function as a drug target and biomarker has also been suggested, making it an attractive target for research and development of new therapeutics. Further research is needed to fully understand the regulation of LINC02919 and its potential as a drug target and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 2919

The "LINC02919 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02919 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets